Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA)

BioIPSeeds Trusted Platform

BioIPSeeds creates a new model for academia-industry interaction by providing an effective, safe and trustful environment.

TRPMA visited the incoming Vice President

Mr Ho led TRPMA representatives to visit Dr Chen Chien-Jen to congratulate his election to next Vice President of Taiwan. The group delivered the industry’s suggestions, hoping to accelerate the industry’s development.

The 5th Cross-strait Biotech Communication Conference

Taiwan: TRPMA and DTCO Jointly Announce the Development of “TRPMA Biopharma Trusted Platform”

Taiwan: TRPMA and DTCO Jointly Announce the Development of “TRPMA Biopharma Trusted Platform”

(Source: TRPMA 2016-05-10）

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA) announced the collaboration with Digital Treasury Corporation (DTCO) to jointly develop the “TRPMA Biopharma Trusted Platform”, an application of the latest Blockchain Technology.

Read More

Welcome to TRPMA website

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), composed of 28 Taiwanese innovative biopharmaceutical companies, plays a pivotal role in coordinating the resources, strengthening alliances among the industry, the academic and the government in Taiwan. TRPMA members aim to create a competitive value chain of biopharmaceutical industry to boost the nation's economy and promote the Asian and global cooperation in biopharmaceutical innovation.

Industry News

US: FDA plans to ramp up disease-focused guidance

FDA Commissioner Scott Gottlieb on Tuesday told a House Appropriations subcommittee that the agency plans to “sharply increase” its release of disease-focused guidance documents to help drugmakers develop new treatments.

Read More
EU: Increasing oversight of API manufacturing through international collaboration

Report on the International API inspection programme published.

Read More
US: Final guidance details sponsor-FDA agreements on trials

The US Food and Drug Administration (FDA) on Friday finalized guidance on the special protocol assessment (SPA), which is the process by which sponsors of pharmaceutical or biologic applications can meet with FDA to discuss the design and size of certain clinical or animal studies to determine if they can adequately support marketing approval.

Read More